Existential questions about the future of vaccine development have been raised by the refusal of the US Food and Drug Administration (FDA) to approve Moderna’s new flu shot.
On February 3, the Cambridge, Mass.-based pharmaceutical giant received a so-called “refusal-to-file” letter (RTF) from the FDA’s Center for Biologics Evaluation and